WO2020214003A1 - B형 간염 바이러스의 증식을 억제하는 조성물 및 이의 방법 - Google Patents
B형 간염 바이러스의 증식을 억제하는 조성물 및 이의 방법 Download PDFInfo
- Publication number
- WO2020214003A1 WO2020214003A1 PCT/KR2020/005203 KR2020005203W WO2020214003A1 WO 2020214003 A1 WO2020214003 A1 WO 2020214003A1 KR 2020005203 W KR2020005203 W KR 2020005203W WO 2020214003 A1 WO2020214003 A1 WO 2020214003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hbv
- seq
- nucleic acid
- virus
- hepatitis
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Definitions
- the present application relates to a method of inhibiting the proliferation of various genotypes of hepatitis B virus.
- the present application relates to a composition for inhibiting the proliferation of various genotypes of hepatitis B virus.
- the present application relates to various uses of compositions for inhibiting the proliferation of hepatitis B viruses of various genotypes.
- Hepatitis B is an inflammation of the liver caused by the hepatitis B virus (HBV).
- Hepatitis B virus infection is not only highly incidence worldwide, but can be infected by anyone, regardless of age or race, and the path of infection varies.
- the hepatitis B therapeutic agent developed so far frequently improves symptoms for some genotypes of hepatitis B, among the genotypes of the hepatitis B virus, where various genotypes exist.
- An object of the present application is to provide a method for suppressing the proliferation of hepatitis B virus by targeting conserved regions of hepatitis B virus of various genotypes.
- Another object of the present application is to provide a composition targeting conserved regions of hepatitis B virus of various genotypes.
- Another object of the present application is to provide a conserved sequence of conserved regions of hepatitis B virus of various genotypes.
- the present application may provide a method of inhibiting the proliferation of hepatitis B virus (HBV) in order to solve the above-described problem.
- HBV hepatitis B virus
- the hepatitis B virus is at least two or more HBV genotypes selected from HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type or HBV G type,
- the guide nucleic acid is characterized in that it comprises any one or more selected from SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 and 89, respectively You can provide a way to do it.
- a method comprising forming an indel in a nucleic acid sequence in a hepatitis B virus gene by the introduction may be provided.
- the present application may provide a method of inactivating a conserved sequence in a hepatitis B virus (HBV) gene in order to solve the above-described problem.
- the hepatitis B virus gene is at least one selected from among HBV genotypes consisting of HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type, or HBV G type, and the
- the conserved sequence is a sequence conserved between the sequences of the HBV genotype, and in this case, the conserved sequence is SEQ ID NO. It is any one or more selected from 1 to 45, and the inactivation is to cleavage the conserved sequence,
- the guide nucleic acid is a sequence that is partially or entirely complementary to the conserved sequence or a sequence having homology, and the guide nucleic acid is SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87, and 89 may provide a method characterized in that each comprises any one or more selected from.
- FIG. 1 is a diagram showing a schematic diagram of the design of CRISPR gRNAs capable of targeting HBV genotypes B, C, and D.
- FIG. 2 is a diagram showing a virtual universal HBV genome for HBV genotype B produced based on an open database.
- FIG. 3 is a diagram showing a virtual universal HBV genome for HBV genotype C produced based on an open database.
- FIG. 4 is a diagram showing a virtual universal HBV genome for HBV genotype D produced based on an open database.
- 5 is a diagram showing the distribution of the gRNA of SpCas9 capable of targeting the virtual universal HBV genotype B or C or D.
- FIG. 6 is a diagram showing the distribution of CjCas9 that can target a virtual universal HBV genotype B or C or D.
- FIG. 7 is a diagram showing the distribution of SpCas9 gRNAs targeting a conserved region based on the derived open database, a HBV genotype C derived from Korean patients, and a region commonly conserved in the sequence of an available HBV cell model. to be.
- FIG. 8 is a diagram showing the distribution of CjCas9 gRNAs targeting a conserved region based on the derived open database, a Korean patient-derived HBV genotype C, and a region commonly conserved in the sequence of an available HBV cell model. to be.
- FIG. 9 is a diagram showing a target region of HBV gRNA of the present application.
- 10 to 13 and 18 are diagrams showing the results of measuring HBsAg and HBeAg of HBV D genotype of gRNA candidates (Cj#06, Cj#45, Cj#47, Cj#57) for CjCas9.
- gRNA candidates for SpCas9 (Sp#17, Sp#20, Sp#89, Sp#90, Sp#154, Sp#159, Sp#193, Sp#194, Sp#196, Sp #197) is a diagram showing the measurement results of HBsAg and HBeAg of the HBV D genotype.
- gRNA candidates for SpCas9 (Sp#17, Sp#90, Sp#193, Sp#197, Sp#17+90+193, Sp#17+90+197, Sp#17+193+197 , Sp#90+193+197) is a diagram showing the results of measuring HBsAg and HBeAg in Huh7 (HBV D genotype) and HepG2 (HBV D genotype) cell lines.
- FIGS. 20 and 21 are diagram summarizing the results of FIGS. 20 and 21.
- HBV genotype A is a diagram showing the results of measuring HBsAg and HBeAg for each.
- FIG. 27 is a diagram showing a vector map designed to express one SpgRNA, Cas9 and a fluorescent protein in one plasmid.
- 28 is a diagram showing a vector map designed to express one CjgRNA, Cas9 and a fluorescent protein in one plasmid.
- 29 is a diagram showing a vector map designed to express three SpgRNAs, Cas9, and a fluorescent protein in one plasmid.
- Hepatitis B is not only one of the widespread infectious diseases around the world, but also a disease that is highly likely to progress to chronic liver diseases such as cirrhosis and liver cancer.
- Hepatitis B virus a hepatitis B virus that causes hepatitis B
- HBV Hepatitis B virus
- hepatitis B virus is a DNA virus belonging to Hepadnaviridae and is an incomplete double helix virus composed of about 3.2 kb (3200 bp) bases.
- HBV has an incomplete complementary structure of positive-stranded DNA located inside the complete circular negative-stranded DNA.
- HBV genome In the HBV genome, four ORFs (open reading frames) overlap, each with genes that designate pre-S/S, C, P, and X.
- the ORF of the HBV genome has more than 50% overlapping portions.
- HBV polymerase overlaps with the entire pre-S/S and with other ORFs. So, mutations that occur during HBV replication can affect more than one ORF, making mutations particularly prone to HBV replication.
- HBV is known to exist in a total of 7 types of genotypes A to G. Each subtype differs by more than 8% on the entire HBV nucleotide sequence.
- HBV The genotype of HBV has distinct distribution patterns depending on the region. In Western Europe and North America, A and D types are known as the main species, and in Asia, B and C types are known as the main species. Type E is confined to Africa and Type F is common in Central America. In particular, there are reports that HBV types B and C maintain viral proliferation for a longer period compared to other types (J Infect Dis 1997; 176:851-858).
- HBV hepatitis B virus
- hepatitis B virus not only causes diseases such as hepatitis and liver cancer, it is known that there are a total of seven different genotypes for HBV genotypes.
- Interferon ⁇ which was first developed as a treatment for hepatitis B, promotes the destruction of HBV-infected hepatocytes by promoting the expression of Major Histocompatibility Complex I (MHC I) antigens in HBV-infected hepatocytes.
- the document EP2014830911 discloses hundreds of guide nucleic acid candidates targeting the conserved region of the hepatitis B virus. Among them, about 24 guide nucleic acid candidates selected for screening whether the proliferation of the hepatitis B virus is inhibited have been disclosed. Furthermore, as a result of the screening, it is reported that about 3 guide nucleic acids that can substantially inhibit the proliferation of hepatitis B virus out of about 24 guide nucleic acid candidates.
- World J Gastroenterol 2015 August 28; 21(32): 9554-9565) also discloses about 15 guide nucleic acid candidates targeting conserved regions of the hepatitis B virus.
- about 15 guide nucleic acids were screened for inhibition of hepatitis B virus alone or in combination, but it is reported that the effects of each guide nucleic acid candidates are different, as in the EP2014830911 document.
- the hepatitis B virus proliferation inhibitory effect is targeting a conserved region of the hepatitis B virus, the hepatitis B virus proliferation inhibitory effect appears only in specific sequences. Therefore, according to this known fact, it can be seen that it is not possible to easily predict that the effect of inhibiting the proliferation of other genotypes of hepatitis B virus occurs only by the effect of inhibiting the proliferation of some genotypes of hepatitis B virus among various genotypes of hepatitis B virus have.
- the present application provides methods and compositions for inhibiting the proliferation of various genotypes of hepatitis B virus.
- the present application is designed to target and extract the conserved region of the hepatitis B virus from a more diverse target than the prior art, thereby providing another specific target sequence having a substantial proliferation inhibitory effect against the hepatitis B virus of various genotypes. Use.
- the present application relates to a composition targeting a specific conserved region of the hepatitis B virus and a method of using the same, in particular, characterized in that it can simultaneously suppress the hepatitis B virus of various genotypes.
- a specific region on the HBV genome targeted in the present application is derived through a method different from the prior art, and this specific region determined in the present application is clearly different from the region disclosed in the prior art.
- the target for extracting a specific region of the hepatitis B virus is derived by combining information from the existing database, information from a patient infected with the hepatitis B virus, and information from the cell line injected with the hepatitis B virus. do.
- the present application is for various HBV genotypes, for example, HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type and HBV G type, treatment considering the sequence of each genotype
- effective treatment methods can be applied to all genotypes using the same sequence (region). That is, it is possible to suppress the proliferation of the hepatitis B virus with one type of composition without great restrictions on various HBV genotypes.
- the method of inhibiting the hepatitis B virus proliferation of the present application is to inactivate a specific sequence conserved in the hepatitis B virus gene.
- the conserved specific sequence is a conserved sequence as a region in which mutation does not occur easily between sequences of various HBV genotypes. Therefore, the method of the present application can be applied without limitation to various HBV genotypes.
- at least two or more HBV genotypes selected from HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type or HBV G type can be simultaneously suppressed.
- composition and method for suppressing the hepatitis B virus proliferation by targeting a specific region of the present application it is possible to exhibit a therapeutic effect using one type of specific region for the hepatitis B virus of various HBV genotypes. That is, by using the same composition and method, hepatitis B according to HBV A, HBV B, HBV C, HBV D, HBV E, HBV F, or HBV G can be treated.
- An aspect of the present application relates to being able to suppress the proliferation of hepatitis B viruses of various genotypes by using a common target region.
- the method of inhibiting the proliferation of the hepatitis B virus of the present application is to suppress the proliferation of the hepatitis B virus by using a technique that targets a common conserved specific region of the hepatitis B virus of various genotypes.
- the genotype of the hepatitis B virus may be selected from HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type and HBV G type, but is not limited thereto.
- the method of inhibiting the proliferation of hepatitis B virus of the present application is one or more genotypes selected from HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type and HBV G type. Hepatitis virus growth can be simultaneously inhibited.
- the term "conserved area” should be interpreted as follows. Hepatitis B virus genotype HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type, or HBV G type. do.
- the target of obtaining the nucleotide sequence of the hepatitis B virus genotype is preserved between the base sequences of the HBV genotype selected by considering both the database, as well as the cell model derived from the patient infected with the hepatitis B virus, and the cell model injected with the hepatitis B virus. Means area.
- the nucleic acid sequence of the conserved region is also referred to as a "conserved sequence”.
- the conserved sequence of the present application can be obtained using the following method. .
- the method of finding the conserved sequence of the hepatitis B virus of various genotypes is a simple method of finding the conserved sequence of the hepatitis B virus of various genotypes
- the conserved sequence obtained by the above method is SEQ ID NO. It may be any one or more selected from 1 to 45.
- AGG Sp20-viHBV-B-#159 AGGAGGCTGTAGGCATAAAT (SEQ ID NO. 25) TGG Sp20-viHBV-B-#186 CGGAAGTGTTGATAAGATAG (SEQ ID NO. 26) GGG Sp20-viHBV-B-#187 CCGGAAGTGTTGATAAGATA (SEQ ID NO. 27) GGG Sp20-viHBV-B-#193 GCGAGGGAGTTCTTCTTCTA (SEQ ID NO. 28) GGG Sp20-viHBV-B-#194 GACCTTCGTCTGCGAGGCGA (SEQ ID NO. 29) GGG Sp20-viHBV-B-#196 GATTGAGACCTTCGTCTGCG (SEQ ID NO.
- AGG Sp20-viHBV-B-#197 CTCCCTCGCCTCGCAGACGA (SEQ ID NO. 31) AGG Sp20-viHBV-B-#198 GATTGAGATCTTCTGCGACG (SEQ ID NO. 32) CGG Sp20-viHBV-B-#199 GTCGCAGAAGATCTCAATCT (SEQ ID NO. 33) CGG Sp20-viHBV-B-#200 TCGCAGAAGATCTCAATCTC (SEQ ID NO. 34) GGG Cj22-viHBV-B-#06 TGTCAACAAGAAAAACCCCGCC (SEQ ID NO.
- the conserved sequence of the present application obtained by the above method is, for example, SEQ ID NO. It may be any one or more selected from 6, 7, 11, 12, 24, 25, 28, 29, 30, 31, 35, 40, 42, and 44.
- the most preferable method of finding the conserved sequence of the hepatitis B virus of various genotypes of the present application is to obtain a target for obtaining the hepatitis B virus nucleotide sequence of various genotypes by expanding, as described above.
- the conserved sequence determined above is SEQ ID NO. 1 to 45, more preferably SEQ ID NO. Sequences of 6, 7, 11, 12, 24, 25, 28, 29, 30, 31, 35, 40, 42, and 44; And a sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, or 100% homology with respect to the sequences.
- the conserved sequence of the hepatitis B virus targeted by the method of the present application described above is, preferably, the base sequence information for the hepatitis B virus of various genotypes, derived from a database, patient-derived, and a variety of cell models. It can be obtained from a combination of subjects.
- the specific conserved sequence determined in this way can be a target capable of inhibiting the proliferation of hepatitis B virus without limitation to the HBV genotype, unlike the conventional case.
- composition of the present application which will be described in more detail below, is designed to target conserved regions of the various genotypes of hepatitis B virus.
- One embodiment of the present application relates to a composition for inhibiting the proliferation of hepatitis B viruses of various genotypes.
- composition targets conserved regions of hepatitis B virus of various genotypes.
- targets collectively refers to a mechanism that induces a sequence modification or inactivation of a function of a conserved region of the hepatitis B virus, thereby exhibiting a proliferation inhibitory or killing effect of the hepatitis B virus.
- composition of the present application for inhibiting the proliferation of various genotypes of hepatitis B virus is not limited as long as it has a function of targeting a predetermined common specific region, that is, a conserved region (sequence).
- a composition capable of introducing a mutation of the conserved region on the hepatitis B virus genomic DNA, or a composition capable of inhibiting translation of the conserved region on the mRNA of the hepatitis B virus may all be included.
- composition of the present application comprises a CRISPR system.
- it may include a guide nucleic acid and a Cas protein targeting the conserved region of the present application.
- This CRISPR system is a system capable of introducing an artificial mutation by targeting a target sequence around a PAM (proto-spacer-adjacent Motif) sequence on genomic DNA.
- the guide nucleic acid and the Cas protein bind to (or interact with each other) to form a guide nucleic acid-Cas protein complex, and by cutting the desired DNA sequence, a mutant indel can be induced on genomic DNA.
- the composition of the present application can inhibit the proliferation or function of the hepatitis virus by introducing indels to the preserved region described above.
- the Cas protein is one or more proteins selected from the group consisting of a Cas9 protein derived from Streptococcus pyogenes (Sp) and a Cas9 protein derived from Campylobacter jejuni (Cj) or encoding it It may include one or more selected from among the following nucleic acid sequences.
- the Cas9 protein functions to recognize a PAM (proto-spacer-adjacent Motif) sequence on a genomic DNA sequence of a subject and to cleave a DNA sequence at a position adjacent to the PAM sequence by interacting with a guide nucleic acid.
- PAM proto-spacer-adjacent Motif
- the guide nucleic acid may be complementary to the target sequence of the hepatitis B virus genomic DNA sequence by using the conserved sequence of the present application as a target sequence.
- the guide nucleic acid includes a site complementary to the target sequence (hereinafter referred to as a guide site) and a site involved in forming a complex with the Cas protein (hereinafter referred to as a complex formation site).
- the guide portion is SEQ ID NO. 1 to 45, more preferably SEQ ID NO. It may be a sequence having homology with the sequence of 6, 7, 11, 12, 24, 25, 28, 29, 30, 31, 35, 40, 42, and 44 or a sequence having complementarity. Even if 0 to 5 mismatches are included in the guide site binding to the target sequence, it is not a problem if there is no effect on the function of the complex.
- the sequence targeting the conserved sequence of the hepatitis B virus may be any one selected from SEQ ID NO.46 to 90 of [Table 2].
- the guide nucleic acid interacts with the SpCas9 protein, and may be any one selected from SEQ ID NO.46 to 79.
- the guide nucleic acid interacts with CjCas9 proteinyl, and may include any one selected from SEQ ID NO.80 to 90.
- the complex formation site may be determined according to the type of the Cas9 protein-derived microorganism.
- the complex formation site may include 5'-GUUUUAGUCCCUGAAAAGGGACUAAAAUAAAGAGUUUGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU-3', and in the case of a CjCas9 GAGUGUGAGCAAAA, the guide that interacts with the CjCas9 GAGUGAGCAAAAAAAA' Can include'.
- the guide site sequence (SEQ ID NOs: 46 to 90) of the guide nucleic acid of the present application is a sequence capable of complementarily binding to SEQ ID NOs: 1 to 45, which are conserved sequences described in Table 1 above, and is adjacent to the conserved sequence. It is designed in consideration of the PAM (proto-spacer-adjacent Motif) sequence that is located.
- NGG N is A, T, C, or G
- cjCas9 protein N is each independently A , T, C or G, R is A or G, and Y is C or T.
- the composition may contain one or more guide nucleic acids.
- the guide nucleic acid of the present application is SEQ ID NO.
- One or more selected from 46 to 90 may be selected and used.
- Preferably, a combination of two or more of the above sequences may be selected and used.
- one of SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87, and 89 may be selected or a combination of two or more may be selected and used. .
- a combination of SEQ ID NO.51, 57 and 73 or a combination of SEQ ID NO.51, 73 and 76 was used.
- composition of the present application for example,
- a guide nucleic acid comprising at least one selected from SEQ ID NO. 51, 52, 56, 57, 69, 70, 73, 74, 75, 76 or a nucleic acid sequence encoding the same; And SpCas protein or a nucleic acid sequence encoding the same.
- a guide nucleic acid comprising one or more selected from SEQ ID NO.80, 85, 87, 89 or a nucleic acid sequence encoding the same; And CjCas protein or a nucleic acid sequence encoding the same.
- composition of the present application is a composition of the present application.
- composition of the present application may be a vector form or a RNP (ribonucleoprotein) form. Therefore, the composition
- a vector including a nucleic acid sequence encoding a guide nucleic acid and/or a Cas protein may be formed at the same time or individually.
- the vector may include a guide nucleic acid and a nucleic acid sequence encoding a Cas protein at the same time, for another example, the vector may individually include a guide nucleic acid and a nucleic acid sequence encoding a Cas protein.
- one or more of the guide nucleic acid and/or Cas protein may be used.
- two or three guide nucleic acids may be used in combination.
- the vector may be a viral vector or a plasmid.
- the viral vector may be one or more selected from the group consisting of retrovirus, lentivirus, adenovirus, adeno-associated virus (AAV), vaccinia virus, poxvirus, and herpes simplex virus.
- the composition is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- the guide nucleic acid of a) is any one selected from SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75 and 76, and the Cas protein of b) is Streptococcus pyogenes ) Derived from Cas9 protein.
- the guide nucleic acid may be a combination of SEQ ID NO.51, 57 and 73 or a combination of SEQ ID NO.51, 73 and 76.
- composition is a mixture of two or more of the composition.
- the guide nucleic acid of a) is SEQ ID NO. It is any one selected from 80, 85, 87, and 89, and the Cas protein of b) may include the Cas9 protein derived from Campylobacter jejuni.
- composition may be configured in the form of RNP (ribonucleoprotein).
- composition of the present application targets a specific conserved region of various hepatitis B viruses, thereby inhibiting proliferation of the virus without significant limitation to the genotype of the hepatitis B virus.
- the guide nucleic acid and Cas protein complex of the composition target the conserved region in the HBV genomic DNA of the hepatitis B virus, and cleavage the double sequence of the conserved region.
- indels that is, artificial mutations are formed in the conserved region to inactivate the virus, thereby inhibiting the proliferation of the hepatitis B virus.
- “Inactivation” means that the target gene or the nucleic acid encoding it does not undergo a normal expression process in a cell, or disables or inhibits its function. This can be achieved by inducing a state in which transcription and/or translation of the target gene or nucleic acid is not possible.
- “Knockout” specifically includes methods of erasing genetic information, eg, when cutting a DNA fragment of a gene, and the like. Through the knockout, it is possible to inhibit transcription and/or translation of a disease-causing gene or a gene having an abnormal function.
- “Knockdown” is specifically blocking the translation of a gene into a protein, and may include blocking the production of an mRNA into a protein using, for example, a specific substance such as iRNA or miRNA.
- composition of the present application in particular, can generate indels by NHEJ on the HBV genome by introducing DNA cleavage into the target sequence of interest. This can exert an effect of inhibiting the proliferation or function of HBV.
- the present application by targeting the conserved region of the hepatitis B virus, proliferation of the hepatitis B virus may be suppressed, and the generation or expression of the hepatitis B virus antigen may be suppressed.
- composition of the present application is a composition of the present application.
- HBV A type Two or more types of HBV selected from HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type, and HBV G type can simultaneously inhibit proliferation.
- It relates to a method for inhibiting the growth of hepatitis B virus by using the above composition.
- the method of inhibiting the proliferation of the hepatitis B virus of the present application may be performed by introducing or administering the composition of the present application to a subject, in which case, the composition is
- Cas protein or a nucleic acid sequence encoding it may include.
- the guide nucleic acid is characterized in that it comprises any one or more selected from SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 and 89, respectively To do.
- indels are formed in the nucleic acid sequence in the hepatitis B virus gene by the composition.
- the method of the present application can simultaneously inhibit proliferation of a plurality of HBV genotype hepatitis B viruses among the various HBV genotype hepatitis B viruses with one and the same composition of the present application.
- the present application relates to a method of inactivating a conserved sequence in a hepatitis B virus (HBV) gene.
- HBV hepatitis B virus
- the method is characterized by targeting a specific conserved sequence irrespective of the hepatitis B virus genotype.
- the conserved sequence is a sequence conserved between sequences of the HBV genotype, for example, the conserved sequence SEQ ID NO. Any one or more selected from 1 to 45, preferably SEQ ID NO. It is intended to inactivate at least one conserved sequence selected from 6, 7, 11, 12, 24, 25, 28, 29, 30, 31, 35, 40, 42, and 44. In this case, the inactivation includes cleavage of the conserved sequence.
- the genotype is not greatly limited, i.e., among HBV genotypes consisting of HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type or HBV G type.
- HBV genotypes consisting of HBV A type, HBV B type, HBV C type, HBV D type, HBV E type, HBV F type or HBV G type.
- One or more viruses of choice can be inactivated.
- the guide nucleic acid may include any one or more selected from SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 and 89 have.
- the guide nucleic acid may be a combination of SEQ ID NO.51, 57 and 73 or a combination of SEQ ID NO.51, 73 and 76.
- the method of the present application is to inactivate the conserved sequence in the hepatitis B virus (HBV) gene.
- HBV hepatitis B virus
- the method of the present application has an effect of treating hepatitis B.
- composition of the present application can be carried out by introducing or administering the composition of the present application to a subject in need of administration.
- the subject may be a mammal infected with the hepatitis B virus, in one embodiment, a human, a monkey, a mouse, a rat, etc., but is not limited thereto.
- HBV A type HBV A type
- HBV B type HBV C type
- HBV D type HBV D type
- HBV E type HBV F type
- HBV G type HBV G type
- the present application since the present application has the effect of simultaneously inhibiting various genotype B-type viruses, using the composition and method of the present application, it is possible to effectively inhibit proliferation regardless of the specific type of infected B-type virus, and B Hepatitis can be cured.
- the administration can be carried out in any convenient manner, such as injection, transfusion, implantation or transplantation.
- the route of administration is subretinal, subcutaneously, intradermaliy, intraocularly, intravitreally, intratumorally, intracutaneous, intramedullary, intramuscular intramuscularly), intravenous (intravenous), intralymphatic (intralymphatic), intraperitoneally, etc. can be selected.
- a single dose of the composition is 104-109 cells per kg body weight of the administration subject, such as 105 to 106 cells/kg (body weight). It may be selected from all integer values within, but is not limited thereto, and may be appropriately prescribed in consideration of the age, health and weight of the subject to be administered, the type of treatment to be received at the same time, the frequency of treatment, if any, and the characteristics of the desired effect. have.
- FIG. 1 shows a schematic diagram of designing CRISPR gRNAs capable of targeting HBV genotypes B, C, and D.
- a genetic scissors capable of multi-targeting all of the genomes of the Korean patient-derived HBV genotype C, HBV genotype B, C, D, and HBV cell models of the open database was designed.
- HBV genotypes HBV genome data base (HBVdb, https://hbvdb.lyon.inserm.fr/HBVdb/HBVdbIndex) for HBV B, C, D genotypes 1638, 2136, and 923 full sequences were collected. The collected sequences were sequenced to create a virtual HBV genome (hereinafter, vHBV) sequence.
- vHBV virtual HBV genome
- the virtual HBV genome sequence B-type, C-type, and D-type were constructed based on a site with 80% sequence homology among the aligned sequences of each of the obtained HBV B-type, C-type, and D-type full sequences (Fig. 2 to 4).
- SEQ ID NO. 91 corresponds to the sequence of FIG. 2
- SEQ ID NO. 92 corresponds to the sequence of FIG. 3
- SEQ ID NO. 93 corresponds to the sequence in FIG. 4.
- FIG. 2 SEQ ID NO. 91 GGACTGTTGGGGTGGAGCCCTCAGGCTCAGGGCaTACTCACAACTGTGCCAGCAGCTCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCTACTCCCtTATCTCCACCTCTAAGGGACACTCATCCTCAGGCCATGCAGTGGAA virtual HBV C genotype sequences (Fig. 3) SEQ ID NO.
- CRISPR target gRNAs were designed based on the virtual universal HBV genome of each of the HBV genotypes B, C, and D types obtained in Example 1.
- the gRNA design for SpCas9 (from Streptococcus pyogenes (5'-NGG-3' for target, 5'-NRG-3' for off-target)) and CjCas9 (from Campylobacter jejuni: 5'-NNNNRYAC-3') is Cas -Designer (http://www.rgenome.net/cas-designer/) was used, and gRNAs with mismatch 1 and 2 as off-targets were excluded.
- vHBV B, C D genotype conserved gRNA was obtained as shown in Figures 5 to 6.
- Target for virtual universal HBV genotype B (gRNA 150 for SpCas9, gRNA 80 for CjCas9)
- target for HBV genotype C gRNA 168 for SpCas9, gRNA 66 for CjCas9
- target for HBV genotype D (GRNA 158 for SpCas9, gRNA target 71 for CjCas9) was derived.
- 34 gRNAs for SpCas9 which can simultaneously target virtual universal HBV genotypes B, C, and D, and 11 gRNAs for CjCas9 were obtained (FIGS. 5 to 6 ).
- the gRNAs of 46 to 90 are gRNAs that can target at least one of the HBV genotypes B, C, and D, among which, SEQ ID NO. 46 to 79 are gRNAs of SpCas9, SEQ ID NO. 80 to 90 are CjCas9 gRNAs.
- SpCas9 gRNAs that can target both four virus-derived HBV C-type viruses and two cell lines (D-type) commonly used in HBV experiments are shown in [Table 2] in SEQ ID NO. 51, 52, 56, 57, 69, 70, 73, 74, 75 and 76, and the gRNA of CjCas9 is SEQ ID NO. 80, 85, 87 and 89.
- the conserved sequence based on the Open database obtained in Example 3 the HBV target site targeted by the gRNA targeting the conserved region in the sequence of the HBV genotpye C and HBV cell model derived from Korean patients was screened as a result of screening the HBV target site of FIG. It was confirmed that at least one of P, X, PreS1, PreS2, C, S, and PreC was targeted.
- a vector construction for introducing the gRNA obtained in Example 3 into cells was prepared (FIGS. 27 to 29 ).
- Fig. 27 is designed to express one SpgRNA, Cas9 and a fluorescent protein in one plasmid.
- Fig. 28 is designed to express one CjgRNA, Cas9, and a fluorescent protein in one plasmid.
- 29 is designed to express three SpgRNAs, Cas9 and a fluorescent protein in one plasmid.
- HBV 1.2 plasmid encoding 1.2 copies of the HBV genome (genotype D, Addgene #51294), pAAV HBV genotype A, B and C (kindly provided by Pei-Jer Chen, Taipei city, Taiwan), Cj gRNA of CRISPR Cas9 (Cj #06, Cj#45, Cj#47, Cj#57) plasmids (Toolgen), Sp CRISPR Cas9 gRNA (Sp#17, Sp#20, Sp#89, Sp#90, Sp#154, Sp#159, Sp#193, Sp#194, Sp#196, Sp#197, N#17, N#90, N#193, N#197, N#17-90-193, N#17-90-197, N# 17-193-197, N#90-193-197) plasmids (Toolgen)
- Human liver cancer cell lines Huh7 and HepG2 were obtained from Korean Cell Line Bank (Seoul, Korea). Cell culture and maintenance are used by adding 10% fetal bovine serum (Capricorn, Ebsdorfer ground, Germany) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA) to Dulbecco's modified Eagle's medium (Welgene, Gyeongsan-si, Korea) I did. The maintenance of the cells was maintained in an incubator maintained at 37°C and 5% CO 2 .
- Huh7 or HepG2 cells were seeded with 4 x 10 ⁇ 5 cells in each well of a 6-well plate, and 1 ⁇ g of replicon and 1 ⁇ g of CRISPR Cas9 (SpCas9 or CjCas9) and a plasmid expressing gRNA were prepared using Lipofectamin 2000. Transfected. After 24 hours, the cell medium was replaced with fresh medium. After 3 days, a supernatant of cells was obtained for ELISA.
- HBsAg ELISA Kit WB-2496, Wantai Pharm Inc., Beijing, China
- HBsAg ELISA Kit WB-2296, Wantai Pharm Inc., Beijing, China
- the absorbance of HBeAg and HBsAg was measured in a wavelength range of 450 nm using the SPECTRA max PLUS 384 Microplate Reader and SoftMax Pro 5.2 program.
- HBeAg and HBsAg were measured for each of the SpCas9 gRNA candidates and the CjCas9 gRNA candidates obtained in Example 3 using HBV D genotype HBV 1.2.
- Cj#47 had the lowest amount of HBeAg and HBsAg (Fig. 10 to 13, Fig. 18). In other words, it could be expected that Cj#47 would have the best effect as a CjCas9 target gRNA.
- SpCas9 gRNA candidates Sp#17, Sp#20, Sp#89, Sp#90, Sp#154, Sp#159, Sp#193, Sp#194, Sp#196, Sp#197 of HBeAg and HBsAg were obtained. As a result of measuring the amount, most of the amount of HBeAg was small, but the amount of HBsAg was relatively high.
- gRNAs targeting the conserved sequence of the hepatitis B virus may have different inhibitory abilities for each of HBeAg and HBsAg.
- HBV type A, HBV type B, HBV type C, and HBV type D (respectively named as Genotype A, Genotype B, Genotype C, and Genotype D) in which pAAV HBV genotypes A, B, C and D were introduced into human liver cancer cell line Huh7.
- HBeAg and HBsAg are different in each of the cell lines of HBV A, HBV B, HBV C, and HBV D types of the spCas9 gRNA candidates, respectively.
- N#193 and N#197 (single gRNA) showed a tendency to decrease HBeAg, but did not decrease HBsAg, but N#17-90. It was confirmed that -193, N#17-193-197 effectively reduced HBeAg and HBsAg.
- N#17-90-193 and N#17-193-197 effectively inhibited HBV of all Genotypes A, B, C, and D.
- the present application relates to a method of inhibiting the proliferation of various genotypes of hepatitis B virus.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Name | sequence (5'→ 3') | PAM |
Sp20-viHBV-B-#10 | GTAACACGAGCAGGGGTCCT (SEQ ID NO. 1) | AGG |
Sp20-viHBV-B-#11 | CCCCGCCTGTAACACGAGCA (SEQ ID NO. 2) | GGG |
Sp20-viHBV-B-#12 | ACCCCGCCTGTAACACGAGC (SEQ ID NO. 3) | AGG |
Sp20-viHBV-B-#13 | AGGACCCCTGCTCGTGTTAC (SEQ ID NO. 4) | AGG |
Sp20-viHBV-B-#14 | ACCCCTGCTCGTGTTACAGG (SEQ ID NO. 5) | CGG |
Sp20-viHBV-B-#17 | CACCACGAGTCTAGACTCTG (SEQ ID NO. 6) | TGG |
Sp20-viHBV-B-#20 | GGACTTCTCTCAATTTTCTA (SEQ ID NO. 7) | GGG |
Sp20-viHBV-B-#52 | CCTACGAACCACTGAACAAA (SEQ ID NO. 8) | TGG |
Sp20-viHBV-B-#53 | CCATTTGTTCAGTGGTTCGT (SEQ ID NO. 9) | AGG |
Sp20-viHBV-B-#54 | CATTTGTTCAGTGGTTCGTA (SEQ ID NO. 10) | GGG |
Sp20-viHBV-B-#89 | GGGTTGCGTCAGCAAACACT (SEQ ID NO. 11) | TGG |
Sp20-viHBV-B-#90 | TTTGCTGACGCAACCCCCAC (SEQ ID NO. 12) | TGG |
Sp20-viHBV-B-#101 | TCCGCAGTATGGATCGGCAG (SEQ ID NO. 13) | AGG |
Sp20-viHBV-B-#102 | AGGAGTTCCGCAGTATGGAT (SEQ ID NO. 14) | CGG |
Sp20-viHBV-B-#103 | TCCTCTGCCGATCCATACTG (SEQ ID NO. 15) | CGG |
Sp20-viHBV-B-#113 | CGTCCCGCGCAGGATCCAGT (SEQ ID NO. 16) | TGG |
Sp20-viHBV-B-#117 | CCGCGGGATTCAGCGCCGAC (SEQ ID NO. 17) | GGG |
Sp20-viHBV-B-#118 | TCCGCGGGATTCAGCGCCGA (SEQ ID NO. 18) | CGG |
Sp20-viHBV-B-#119 | CCCGTCGGCGCTGAATCCCG (SEQ ID NO. 19) | CGG |
Sp20-viHBV-B-#138 | GTAAAGAGAGGTGCGCCCCG (SEQ ID NO. 20) | TGG |
Sp20-viHBV-B-#140 | GGGGCGCACCTCTCTTTACG (SEQ ID NO. 21) | CGG |
Sp20-viHBV-B-#142 | GAAGCGAAGTGCACACGGTC (SEQ ID NO. 22) | CGG |
Sp20-viHBV-B-#143 | GGTCTCCATGCGACGTGCAG (SEQ ID NO. 23) | AGG |
Sp20-viHBV-B-#154 | AATGTCAACGACCGACCTTG (SEQ ID NO. 24) | AGG |
Sp20-viHBV-B-#159 | AGGAGGCTGTAGGCATAAAT (SEQ ID NO. 25) | TGG |
Sp20-viHBV-B-#186 | CGGAAGTGTTGATAAGATAG (SEQ ID NO. 26) | GGG |
Sp20-viHBV-B-#187 | CCGGAAGTGTTGATAAGATA (SEQ ID NO. 27) | GGG |
Sp20-viHBV-B-#193 | GCGAGGGAGTTCTTCTTCTA (SEQ ID NO. 28) | GGG |
Sp20-viHBV-B-#194 | GACCTTCGTCTGCGAGGCGA (SEQ ID NO. 29) | GGG |
Sp20-viHBV-B-#196 | GATTGAGACCTTCGTCTGCG (SEQ ID NO. 30) | AGG |
Sp20-viHBV-B-#197 | CTCCCTCGCCTCGCAGACGA (SEQ ID NO. 31) | AGG |
Sp20-viHBV-B-#198 | GATTGAGATCTTCTGCGACG (SEQ ID NO. 32) | CGG |
Sp20-viHBV-B-#199 | GTCGCAGAAGATCTCAATCT (SEQ ID NO. 33) | CGG |
Sp20-viHBV-B-#200 | TCGCAGAAGATCTCAATCTC (SEQ ID NO. 34) | GGG |
Cj22-viHBV-B-#06 | TGTCAACAAGAAAAACCCCGCC (SEQ ID NO. 35) | TGTAACAC |
Cj22-viHBV-B-#20 | AAGCCCTACGAACCACTGAACA (SEQ ID NO. 36) | AATGGCAC |
Cj22-viHBV-B-#23 | TTACCAATTTTCTTTTGTCTTT (SEQ ID NO. 37) | GGGTATAC |
Cj22-viHBV-B-#40 | ACGTCCCGCGCAGGATCCAGTT (SEQ ID NO. 38) | GGCAGCAC |
Cj22-viHBV-B-#44 | GTGCACACGGTCCGGCAGATGA (SEQ ID NO. 39) | GAAGGCAC |
Cj22-viHBV-B-#45 | GTGCCTTCTCATCTGCCGGACC (SEQ ID NO. 40) | GTGTGCAC |
Cj22-viHBV-B-#46 | CGACGTGCAGAGGTGAAGCGAA (SEQ ID NO. 41) | GTGCACAC |
Cj22-viHBV-B-#47 | TGCGACGTGCAGAGGTGAAGCG (SEQ ID NO. 42) | AAGTGCAC |
Cj22-viHBV-B-#48 | GACCGTGTGCACTTCGCTTCAC (SEQ ID NO. 43) | CTCTGCAC |
Cj22-viHBV-B-#57 | ATGTCCATGCCCCAAAGCCACC (SEQ ID NO. 44) | CAAGGCAC |
Cj22-viHBV-B-#67 | GACCACCAAATGCCCCTATCTT (SEQ ID NO. 45) | ATCAACAC |
NO. | Name | sequence (5'→ 3') |
SEQ ID NO. 46 | Sp20-viHBV-B-#10G | GUAACACGAGCAGGGGUCCU |
SEQ ID NO. 47 | Sp20-viHBV-B-#11G | CCCCGCCUGUAACACGAGCA |
SEQ ID NO. 48 | Sp20-viHBV-B-#12G | ACCCCGCCUGUAACACGAGC |
SEQ ID NO. 49 | Sp20-viHBV-B-#13G | AGGACCCCUGCUCGUGUUAC |
SEQ ID NO. 50 | Sp20-viHBV-B-#14G | ACCCCUGCUCGUGUUACAGG |
SEQ ID NO. 51 | Sp20-viHBV-B-#17G | CACCACGAGUCUAGACUCUG |
SEQ ID NO. 52 | Sp20-viHBV-B-#20G | GGACUUCUCUCAAUUUUCUA |
SEQ ID NO. 53 | Sp20-viHBV-B-#52G | CCUACGAACCACUGAACAAA |
SEQ ID NO. 54 | Sp20-viHBV-B-#53G | CCAUUUGUUCAGUGGUUCGU |
SEQ ID NO. 55 | Sp20-viHBV-B-#54G | CAUUUGUUCAGUGGUUCGUA |
SEQ ID NO. 56 | Sp20-viHBV-B-#89G | GGGUUGCGUCAGCAAACACU |
SEQ ID NO. 57 | Sp20-viHBV-B-#90G | UUUGCUGACGCAACCCCCAC |
SEQ ID NO. 58 | Sp20-viHBV-B-#101G | UCCGCAGUAUGGAUCGGCAG |
SEQ ID NO. 59 | Sp20-viHBV-B-#102G | AGGAGUUCCGCAGUAUGGAU |
SEQ ID NO. 60 | Sp20-viHBV-B-#103G | UCCUCUGCCGAUCCAUACUG |
SEQ ID NO. 61 | Sp20-viHBV-B-#113G | CGUCCCGCGCAGGAUCCAGU |
SEQ ID NO. 62 | Sp20-viHBV-B-#117G | CCGCGGGAUUCAGCGCCGAC |
SEQ ID NO. 63 | Sp20-viHBV-B-#118G | UCCGCGGGAUUCAGCGCCGA |
SEQ ID NO. 64 | Sp20-viHBV-B-#119G | CCCGUCGGCGCUGAAUCCCG |
SEQ ID NO. 65 | Sp20-viHBV-B-#138G | GUAAAGAGAGGUGCGCCCCG |
SEQ ID NO. 66 | Sp20-viHBV-B-#140G | GGGGCGCACCUCUCUUUACG |
SEQ ID NO. 67 | Sp20-viHBV-B-#142G | GAAGCGAAGUGCACACGGUC |
SEQ ID NO. 68 | Sp20-viHBV-B-#143G | GGUCUCCAUGCGACGUGCAG |
SEQ ID NO. 69 | Sp20-viHBV-B-#154G | AAUGUCAACGACCGACCUUG |
SEQ ID NO. 70 | Sp20-viHBV-B-#159G | AGGAGGCUGUAGGCAUAAAU |
SEQ ID NO. 71 | Sp20-viHBV-B-#186G | CGGAAGUGUUGAUAAGAUAG |
SEQ ID NO. 72 | Sp20-viHBV-B-#187G | CCGGAAGUGUUGAUAAGAUA |
SEQ ID NO. 73 | Sp20-viHBV-B-#193G | GCGAGGGAGUUCUUCUUCUA |
SEQ ID NO. 74 | Sp20-viHBV-B-#194G | GACCUUCGUCUGCGAGGCGA |
SEQ ID NO. 75 | Sp20-viHBV-B-#196G | GAUUGAGACCUUCGUCUGCG |
SEQ ID NO. 76 | Sp20-viHBV-B-#197G | CUCCCUCGCCUCGCAGACGA |
SEQ ID NO. 77 | Sp20-viHBV-B-#198G | GAUUGAGAUCUUCUGCGACG |
SEQ ID NO. 78 | Sp20-viHBV-B-#199G | GUCGCAGAAGAUCUCAAUCU |
SEQ ID NO. 79 | Sp20-viHBV-B-#200G | UCGCAGAAGAUCUCAAUCUC |
SEQ ID NO. 80 | Cj22-viHBV-B-#06G | UGUCAACAAGAAAAACCCCGCC |
SEQ ID NO. 81 | Cj22-viHBV-B-#20G | AAGCCCUACGAACCACUGAACA |
SEQ ID NO. 82 | Cj22-viHBV-B-#23G | UUACCAAUUUUCUUUUGUCUUU |
SEQ ID NO. 83 | Cj22-viHBV-B-#40G | ACGUCCCGCGCAGGAUCCAGUU |
SEQ ID NO. 84 | Cj22-viHBV-B-#44G | GUGCACACGGUCCGGCAGAUGA |
SEQ ID NO. 85 | Cj22-viHBV-B-#45G | GUGCCUUCUCAUCUGCCGGACC |
SEQ ID NO. 86 | Cj22-viHBV-B-#46G | CGACGUGCAGAGGUGAAGCGAA |
SEQ ID NO. 87 | Cj22-viHBV-B-#47G | UGCGACGUGCAGAGGUGAAGCG |
SEQ ID NO. 88 | Cj22-viHBV-B-#48G | GACCGUGUGCACUUCGCUUCAC |
SEQ ID NO. 89 | Cj22-viHBV-B-#57G | AUGUCCAUGCCCCAAAGCCACC |
SEQ ID NO. 90 | Cj22-viHBV-B-#67G | GACCACCAAAUGCCCCUAUCUU |
virtual HBV B genotype sequences (도 2) SEQ ID NO. 91GGACTGTTGGGGTGGAGCCCTCAGGCTCAGGGCaTACTCACAACTGTGCCAGCAGCTCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCTACTCCCtTATCTCCACCTCTAAGGGACACTCATCCTCAGGCCATGCAGTGGAA |
virtual HBV C genotype sequences (도 3) SEQ ID NO. 92gGTCTTTTGGGGTGGAGCCCTCAGGCTCAGGGCATATTGACAACAGTGCCAGcAGCaCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGACAGCCTACTCCCATCTCTCCACCTCTAAGAGACAGTCATCCTCAGGCCATGCAGTGGAA |
virtual HBV D genotype sequences (도 4) SEQ ID NO. 93ATAcTACAAACcTTGCCAGCAAATCCGCCTCCTGCcTCtACCAATCGCCAGTCAGGAAGGCAGCCTACCCCgCTGTCTCCACCTTTGAGAAACACTCATCCTCAGGCCATGCAGTGGAA |
NO. | Name | Note. | cccDNA target region |
SEQ ID NO. 51 | Sp20-viHBV-B-#17G | SpCas9 target | P, PreS1, PreS2, S |
SEQ ID NO. 52 | Sp20-viHBV-B-#20G | P, PreS1, PreS2, S | |
SEQ ID NO. 56 | Sp20-viHBV-B-#89G | P | |
SEQ ID NO. 57 | Sp20-viHBV-B-#90G | P | |
SEQ ID NO. 69 | Sp20-viHBV-B-#154G | X | |
SEQ ID NO. 70 | Sp20-viHBV-B-#159G | X | |
SEQ ID NO. 73 | Sp20-viHBV-B-#193G | P, SP, PreC, C | |
SEQ ID NO. 74 | Sp20-viHBV-B-#194G | P, SP, PreC, C | |
SEQ ID NO. 75 | Sp20-viHBV-B-#196G | P, SP, PreC, C | |
SEQ ID NO. 76 | Sp20-viHBV-B-#197G | P, SP, PreC, C | |
SEQ ID NO. 80 | Cj22-viHBV-B-#06G | CjCas9 target | P, PreS1, PreS2, S |
SEQ ID NO. 85 | Cj22-viHBV-B-#45G | P, X | |
SEQ ID NO. 87 | Cj22-viHBV-B-#47G | P, X | |
SEQ ID NO. 89 | Cj22-viHBV-B-#57G | PreC |
Claims (17)
- B형 간염 바이러스(Hepatitis B virus, HBV)의 증식을 억제하는 방법으로서,상기 B형 간염 바이러스는 적어도 HBV A형, HBV B형, HBV C형, HBV D형, HBV E형, HBV F형 또는 HBV G형 중 선택되는 2이상의 HBV 유전자형이고,상기 방법은,a) 가이드핵산 또는 이를 암호화하는 핵산서열; 및b) Cas단백질 또는 이를 암호화하는 핵산서열;을대상에 도입함;을 포함하고,이 때, 상기 가이드핵산은 SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 및 89 중 선택되는 어느 하나 이상을 각각 포함하고,상기 도입으로 B형 간염 바이러스 유전자 내 핵산서열에 인델(indel)을 형성시키는 것을 특징으로 하는 방법.
- B형 간염 바이러스(Hepatitis B virus, HBV) 유전자 내 보존된 서열을 불활성화하는 방법으로서,상기 B형 간염 바이러스 유전자는 적어도 HBV A형, HBV B형, HBV C형, HBV D형, HBV E형, HBV F형 또는 HBV G형으로 구성된 HBV 유전자형 중 선택되는 1이상이고,상기 보존된 서열은 상기 HBV 유전자형의 서열간 보존되는 서열이고,이 때, 상기 보존된 서열은 SEQ ID NO. 1 내지 45 중 선택되는 어느 하나 이상이고,상기 불활성화는 상기 보존된 서열을 절단(cleavage)하는 것이고,상기 방법은,a) 가이드핵산 또는 이를 암호화하는 핵산서열; 및b) Cas단백질 또는 이를 암호화하는 핵산서열;을대상에 도입함;을 포함하고,상기 가이드핵산은 상기 보존된 서열과 일부 또는 전체가 상보적인 서열 또는 상동성을 가진 서열이고,이 때, 상기 가이드핵산은 SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 및 89 중 선택되는 어느 하나 이상을 각각 포함하는것을 특징으로 하는 방법.
- 제 1항 또는 2항에 있어서,상기 Cas단백질은 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9단백질 중 선택되는 하나 이상인 것을 특징으로 하는 방법.
- 제 1항 또는 2항에 있어서,a) 의 가이드핵산은 SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75 및 76 중 선택되는 어느 하나이고, b)의 Cas단백질은 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9단백질인 것을 특징으로 하는 방법.
- 제 1항 또는 2항에 있어서,a)의 가이드핵산은 SEQ ID NO. 80, 85, 87 및 89 중 선택되는 어느 하나이고, b)의 Cas단백질은 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9단백질인 것을 특징으로 하는 방법.
- 제 1항 또는 2항에 있어서,상기 가이드핵산과 Cas단백질은 벡터의 형태로 도입되는 것을 특징으로 하는 방법.
- 제 6항에 있어서,상기 벡터는 레트로바이러스, 렌티바이러스, 아데노바이러스, 아데노-연관 바이러스(AAV), 백시니아바이러스, 폭스바이러스 및 단순포진 바이러스로 구성된 군에서 선택되는 1 이상의 벡터인 것을 특징으로 하는 방법.
- 제 4항에 있어서,상기 가이드핵산은SEQ ID NO.51, 57 및 73 이 함께 도입되는 것을 특징으로 하는 방법.
- 제 4항에 있어서,상기 가이드핵산은SEQ ID NO.51, 73 및 76 이 함께 도입되는 것을 특징으로 하는 방법.
- 제 1항 또는 2항에 있어서,상기 B형 간염 바이러스의 항원인 HBeAg, HBsAg 중 선택되는 어느 하나 이상이 억제되는 것을 특징으로 하는 방법.
- B형 간염 바이러스(Hepatitis B virus, HBV) 게놈 내 보존된 서열을 표적하는 B형 간염 바이러스의 증식을 억제하는 조성물로서,상기 조성물은,a) 가이드핵산 또는 이를 암호화하는 핵산서열; 및b) Cas단백질 또는 이를 암호화하는 핵산서열;을 포함하고,상기 가이드핵산은 SEQ ID NO. 51, 52, 56, 57, 69, 70, 73, 74, 75, 76, 80, 85, 87 및 89 중 선택되는 어느 하나 이상을 각각 포함하고,상기 보존된 서열은 SEQ ID NO. 1 내지 45 중 선택되는 어느 하나 이상인 것을 특징으로 하는 조성물.
- 제 11항에 있어서,상기 Cas단백질은 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9단백질, 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9단백질 중 선택되는 하나 이상인 것을 특징으로 하는 조성물.
- 제 11항에 있어서,상기 조성물은 벡터 형태인 것을 특징으로 하는 조성물.
- 제 11항에 있어서,a)의 가이드핵산은 SEQ ID NO.51, 52, 56, 57, 69, 70, 73, 74, 75 및 76 중 선택되는 어느 하나이고, b)의 Cas단백질은 스트렙토코커스 피요게네스(Streptococcus pyogenes) 유래의 Cas9단백질인 것을 특징으로 하는 조성물.
- 제 11항에 있어서,a)의 가이드핵산은 SEQ ID NO. 80, 85, 87 및 89 중 선택되는 어느 하나이고, b)의 Cas단백질은 캄필로박터 제주니 (Campylobacter jejuni) 유래의 Cas9단백질인 것을 특징으로 하는 조성물.
- 제 11항에 있어서,상기 조성물은 SEQ ID NO.51, 57 및 73을 포함하는 가이드 핵산을 포함하는 것을 특징으로 하는 조성물.
- 제 11항에 있어서,상기 조성물은 SEQ ID NO.51, 73 및 76을 포함하는 가이드 핵산을 포함하는 것을 특징으로 하는 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/604,498 US20230293645A1 (en) | 2019-04-18 | 2020-04-20 | Composition and method for inhibiting proliferation hepatitis b virus |
AU2020258778A AU2020258778A1 (en) | 2019-04-18 | 2020-04-20 | Composition and method for inhibiting proliferation of hepatitis B virus |
CN202080038655.1A CN114008200A (zh) | 2019-04-18 | 2020-04-20 | 用于抑制乙型肝炎病毒增殖的组合物和方法 |
CA3137184A CA3137184A1 (en) | 2019-04-18 | 2020-04-20 | Composition and method for inhibiting proliferation of hepatitis b virus |
EP20791867.3A EP3957734A4 (en) | 2019-04-18 | 2020-04-20 | COMPOSITION AND METHODS TO INHIBIT HEPATITIS B VIRUS PROLIFERATION |
JP2021562027A JP2022529481A (ja) | 2019-04-18 | 2020-04-20 | B型肝炎ウイルスの増殖を抑制する組成物及びその方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835628P | 2019-04-18 | 2019-04-18 | |
US62/835,628 | 2019-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020214003A1 true WO2020214003A1 (ko) | 2020-10-22 |
Family
ID=72838178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/005203 WO2020214003A1 (ko) | 2019-04-18 | 2020-04-20 | B형 간염 바이러스의 증식을 억제하는 조성물 및 이의 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230293645A1 (ko) |
EP (1) | EP3957734A4 (ko) |
JP (1) | JP2022529481A (ko) |
KR (1) | KR20200123392A (ko) |
CN (1) | CN114008200A (ko) |
AU (1) | AU2020258778A1 (ko) |
CA (1) | CA3137184A1 (ko) |
WO (1) | WO2020214003A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105647922A (zh) * | 2016-01-11 | 2016-06-08 | 中国人民解放军疾病预防控制所 | 基于一种新gRNA序列的CRISPR-Cas9系统在制备乙肝治疗药物中的应用 |
KR20160089530A (ko) * | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Hbv 및 바이러스 질병 및 질환을 위한 crisprcas 시스템 및 조성물의 전달,용도 및 치료적 적용 |
WO2016197132A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
KR20170126636A (ko) | 2016-05-10 | 2017-11-20 | 주식회사 코맥스 | 디지털 도어락 시스템 및 이의 동작방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015201226A1 (en) * | 2011-04-21 | 2015-04-02 | Ionis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
JP2017506893A (ja) * | 2014-02-18 | 2017-03-16 | デューク ユニバーシティ | ウイルス複製不活化組成物並びにその製造方法及び使用 |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
CN104711257B (zh) * | 2015-02-09 | 2017-11-03 | 鲁凤民 | 用于乙型肝炎病毒感染治疗的导向rna靶点 |
CA3000170A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Antiviral methods and compositions |
AU2016341919A1 (en) * | 2015-10-21 | 2018-04-19 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating hepatitis b virus |
WO2017213898A2 (en) * | 2016-06-07 | 2017-12-14 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided compositions for preventing and treating hepatitis b virus infections |
CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | LIPID NANOPARTICLE MEDIA ADMINISTRATION OF PLASMIDIC DNA EXPRESSING CRISPR FOR THE TREATMENT OF CHRONIC INFECTION WITH HEPATITIS B VIRUS |
-
2020
- 2020-04-20 EP EP20791867.3A patent/EP3957734A4/en active Pending
- 2020-04-20 KR KR1020200047240A patent/KR20200123392A/ko unknown
- 2020-04-20 US US17/604,498 patent/US20230293645A1/en active Pending
- 2020-04-20 CA CA3137184A patent/CA3137184A1/en active Pending
- 2020-04-20 CN CN202080038655.1A patent/CN114008200A/zh active Pending
- 2020-04-20 WO PCT/KR2020/005203 patent/WO2020214003A1/ko active Application Filing
- 2020-04-20 JP JP2021562027A patent/JP2022529481A/ja active Pending
- 2020-04-20 AU AU2020258778A patent/AU2020258778A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160089530A (ko) * | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Hbv 및 바이러스 질병 및 질환을 위한 crisprcas 시스템 및 조성물의 전달,용도 및 치료적 적용 |
WO2016197132A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
CN105647922A (zh) * | 2016-01-11 | 2016-06-08 | 中国人民解放军疾病预防控制所 | 基于一种新gRNA序列的CRISPR-Cas9系统在制备乙肝治疗药物中的应用 |
KR20170126636A (ko) | 2016-05-10 | 2017-11-20 | 주식회사 코맥스 | 디지털 도어락 시스템 및 이의 동작방법 |
Non-Patent Citations (4)
Title |
---|
DONG, C. ET AL.: "Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication", ANTIVIRAL RESEARCH, vol. 118, 2015, pages 110 - 117, XP029216847, DOI: 10.1016/j.antiviral.2015.03.015 * |
J INFECT DIS, vol. 176, 1997, pages 851 - 858 |
LIU, X. ET AL.: "Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome", JOURNAL OF GENERAL VIROLOGY, vol. 96, 2015, pages 2252 - 2261, XP055607947, DOI: 10.1099/vir.0.000159 * |
WORLD J, GASTROENTEROL, vol. 21, no. 32, 28 August 2015 (2015-08-28), pages 9554 - 9565 |
Also Published As
Publication number | Publication date |
---|---|
EP3957734A1 (en) | 2022-02-23 |
CA3137184A1 (en) | 2020-10-22 |
US20230293645A1 (en) | 2023-09-21 |
JP2022529481A (ja) | 2022-06-22 |
CN114008200A (zh) | 2022-02-01 |
EP3957734A4 (en) | 2023-03-08 |
AU2020258778A1 (en) | 2021-11-11 |
KR20200123392A (ko) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016111546A9 (ko) | 혈액 응고인자 viii 유전자를 타겟으로 하는 엔도뉴클레아제 및 이를 포함하는 혈우병 치료용 조성물 | |
WO2016021973A1 (ko) | 캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정 | |
WO2017003267A1 (ko) | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2012165854A9 (ko) | 표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 rna | |
WO2018208011A2 (ko) | β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드 | |
WO2020005028A1 (ko) | 중증 열성 혈소판 감소 증후군(sfts) 바이러스 감염 질환 예방 또는 치료용 백신 조성물 | |
WO2020214003A1 (ko) | B형 간염 바이러스의 증식을 억제하는 조성물 및 이의 방법 | |
WO2021221435A1 (ko) | 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물 | |
WO2012134215A2 (ko) | 동물세포 발현벡터 | |
WO2019143201A1 (ko) | 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물 | |
WO2016085284A1 (ko) | B형 간염 바이러스 표면 항원의 에피토프 및 이에 특이적으로 결합하는 b형 간염 바이러스 중화 결합 분자 | |
WO2016199964A1 (ko) | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 | |
WO2022124839A1 (ko) | 온-타겟 활성이 유지되고 오프-타겟 활성이 감소된 가이드 rna 및 이의 용도 | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2019212312A1 (ko) | 키메라 지카바이러스 백신 | |
WO2018194438A1 (ko) | 비복제 아데노 바이러스 생산 세포주 및 이의 제조방법 | |
WO2019031804A9 (ko) | 목적 유전자 발현 조절을 위한 대장균 및 코리네박테리움 글루타미쿰 셔틀 벡터 | |
WO2018236194A1 (ko) | Gas6 단백질 또는 이의 수용체 활성화제를 포함하는 섬유증의 예방 또는 치료용 조성물 | |
WO2023211172A1 (ko) | 유방암 세포 계대를 통한 키메라 지카바이러스 항암백신 | |
WO2023282704A1 (ko) | Marc1 유전자를 표적으로 하는 rnai 제제 및 이의 용도 | |
WO2023229422A1 (ko) | 지카바이러스 감염성 전장 클론 또는 이의 변이체 및 이들의 용도 | |
WO2023128051A1 (ko) | 돼지생식기호흡기증후군바이러스 유래 펩타이드를 발현하는 키메라 바이러스 및 이를 포함하는 백신 조성물 | |
WO2015194770A1 (ko) | Bst2 유전자의 기능이 상실된 세포주를 이용한 바이러스 감염 촉진 및 생산 증진 방법 | |
WO2021145700A1 (ko) | 저산소 환경 하에서 높은 적응력을 가지는 세포 및 이의 용도 | |
AU2020299074B2 (en) | Novel ribonucleic acid and pharmaceutical composition based on the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20791867 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3137184 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021562027 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020258778 Country of ref document: AU Date of ref document: 20200420 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020791867 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2020791867 Country of ref document: EP Effective date: 20211118 |